Literature DB >> 29045711

The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?

Marcus Unterrainer1, Maximilian Niyazi1, Viktoria Ruf1, Peter Bartenstein1, Nathalie L Albert1.   

Abstract

Entities:  

Keywords:  PSMA; glioma; gliosarcoma; theranostics

Mesh：

Substances：

Year:  2017        PMID： 29045711      PMCID： PMC5716188          DOI： 10.1093/neuonc/nox172

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer.

Authors:  Uwe Haberkorn; Klaus Kopka; Boris Hadaschik
Journal:  Eur Urol       Date:  2015-09-14       Impact factor: 20.096

2.  Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.

Authors:  Katharina Seystahl; Veit Stoecklein; Ulrich Schüller; Elisabeth Rushing; Guillaume Nicolas; Niklaus Schäfer; Harun Ilhan; Athina Pangalu; Michael Weller; Jörg-Christian Tonn; Michael Sommerauer; Nathalie L Albert
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

3.  In vivo visualization of prostate-specific membrane antigen in glioblastoma.

Authors:  Johannes Schwenck; Ghazaleh Tabatabai; Marco Skardelly; Gerhald Reischl; Rudi Beschorner; Bernd Pichler; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-08       Impact factor: 9.236

4.  Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.

Authors:  A Gabriella Wernicke; Mark A Edgar; Ehud Lavi; He Liu; Pamela Salerno; Neil H Bander; Philip H Gutin
Journal:  Arch Pathol Lab Med       Date:  2011-11       Impact factor: 5.534

5.  Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis.

Authors:  Arun Sasikumar; Ajith Joy; M R A Pillai; Raviteja Nanabala; Muhammed Anees K; P G Jayaprakash; Jayaprakash Madhavan; Suresh Nair
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

6.  Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.

Authors:  Natsuko Nomura; Sandra Pastorino; Pengfei Jiang; Gage Lambert; John R Crawford; Marco Gymnopoulos; David Piccioni; Tiffany Juarez; Sandeep C Pingle; Milan Makale; Santosh Kesari
Journal:  Cancer Cell Int       Date:  2014-03-20       Impact factor: 5.722
  6 in total
  9 in total

Review 1.  The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors.

Authors:  Ilanah J Pruis; Guus A M S van Dongen; Sophie E M Veldhuijzen van Zanten
Journal:  Int J Mol Sci       Date:  2020-02-04       Impact factor: 5.923

2.  PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging.

Authors:  Adrien Holzgreve; Annamaria Biczok; Viktoria C Ruf; Friederike Liesche-Starnecker; Katja Steiger; Maximilian A Kirchner; Marcus Unterrainer; Lena Mittlmeier; Jochen Herms; Jürgen Schlegel; Peter Bartenstein; Jörg-Christian Tonn; Nathalie L Albert; Bogdana Suchorska
Journal:  Front Oncol       Date:  2021-03-30       Impact factor: 6.244

3.  Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.

Authors:  Li-Xing Chen; Si-Juan Zou; Dan Li; Jian-Yuan Zhou; Zhao-Ting Cheng; Jun Zhao; Yuan-Li Zhu; Dong Kuang; Xiao-Hua Zhu
Journal:  World J Gastroenterol       Date:  2020-12-28       Impact factor: 5.742

4.  PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook.

Authors:  Maximilian A Kirchner; Adrien Holzgreve; Matthias Brendel; Michael Orth; Viktoria C Ruf; Katja Steiger; Dennis Pötter; Lukas Gold; Marcus Unterrainer; Lena M Mittlmeier; Enio Barci; Roland E Kälin; Rainer Glass; Simon Lindner; Lena Kaiser; Jessica Maas; Louisa von Baumgarten; Harun Ilhan; Claus Belka; Johannes Notni; Peter Bartenstein; Kirsten Lauber; Nathalie L Albert
Journal:  Front Oncol       Date:  2021-11-17       Impact factor: 6.244

Review 5.  Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.

Authors:  Brittany M Stopa; James Crowley; Csaba Juhász; Cara M Rogers; Mark R Witcher; Jackson W Kiser
Journal:  Mol Imaging       Date:  2022-04-15       Impact factor: 3.250

6.  PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?

Authors:  Winfried Brenner; Joachim Strobel; Vikas Prasad
Journal:  J Nucl Med       Date:  2021-07-16       Impact factor: 10.057

Review 7.  Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors.

Authors:  Jan-Michael Werner; Philipp Lohmann; Gereon R Fink; Karl-Josef Langen; Norbert Galldiks
Journal:  Molecules       Date:  2020-03-24       Impact factor: 4.411

8.  Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas.

Authors:  Francesco Bertagna; Domenico Albano; Elisabetta Cerudelli; Maria Gazzilli; Raffaele Giubbini; Giorgio Treglia
Journal:  Curr Radiopharm       Date:  2020

Review 9.  Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.

Authors:  Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.